

Special Issue

Neurodegenerative Diseases: Recent Advances and Future Perspectives

Message from the Guest Editors

Neurodegenerative diseases affect millions of people worldwide and their incidence is on the rise due to the increasing life expectancy. These diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, ataxias and glaucoma, encompass a range of conditions that result in progressive neuronal damage and connectivity, affecting mobility, coordination, strength, sensation, and cognition. This Special Issue, edited by Dr. López-Cuenca and Dr. De Hoz, will focus on the latest advances in research on neurodegenerative diseases, including basic, translational and clinical sciences, with the aim of expanding knowledge on the pathophysiological mechanisms and therapeutic perspective of these diseases.

Guest Editors

Dr. Inés López-Cuenca

1. Ramon Castroviejo Institute of Ophthalmologic Research, Complutense University of Madrid, 28040 Madrid, Spain
2. Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain

Dr. Rosa De Hoz

1. Ramon Castroviejo Institute of Ophthalmologic Research, Complutense University of Madrid, 28040 Madrid, Spain
2. Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
3. Department of Immunology, Ophthalmology and ENT, Faculty of Optics and Optometry, Complutense University of Madrid, 28037 Madrid, Spain

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/158098

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).